Rifaximin SSD — Competitive Intelligence Brief

Rifaximin SSD (Rifaximin SSD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Gastroenterology.

phase 3 Rifamycin antibiotic Bacterial RNA polymerase Gastroenterology Small molecule

Target snapshot

Rifaximin SSD (Rifaximin SSD) — Bausch Health Americas, Inc.. Rifaximin SSD is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifaximin SSD TARGET	Rifaximin SSD	Bausch Health Americas, Inc.	phase 3	Rifamycin antibiotic	Bacterial RNA polymerase
Vancomycin plus Rifampin	Vancomycin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin)
Rifaximin and loperamide	Rifaximin and loperamide	The University of Texas Health Science Center, Houston	marketed	Antibiotic + antidiarrheal combination	Bacterial RNA polymerase (rifaximin); mu-opioid receptors in the GI tract (loperamide)
RIF	RIF	South China Children's Leukemia Group	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
PB 6 doses - Rifampicin and Dapsone	PB 6 doses - Rifampicin and Dapsone	University of Brasilia	marketed	Antileprosy combination therapy	Bacterial RNA polymerase (rifampicin); dihydropteroate synthase (dapsone)
amoxicillin rifabutin	amoxicillin rifabutin	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic (beta-lactam + rifamycin)	Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class